- All > Quality and Safety: Medicines > Blood Products and Related Biologicals
- All > Quality and Safety: Medicines > Quality Assurance
- Keywords > biological products
- Keywords > biological standardization
- Keywords > biologicals - International Standards and Reference
- Keywords > biologicals - manufacture and quality control
- Keywords > blood products and related substances
- Keywords > vaccines - stability evaluation
- Keywords > vaccines - standards
- Keywords > vaccines and related substances
- Keywords > WHO expert committee
(2017; 616 pages)
This report presents the recommendations of a WHO Expert Committee commissioned to coordinate activities leading to the adoption of international recommendations for the production and control of vaccines and other biological substances, and the establishment of international biological reference materials.
Following a brief introduction, the report summarizes a number of general issues brought to the attention of the Committee. The next part of the report, of particular relevance to manufacturers and national regulatory authorities, outlines the discussions held on the development and revision of WHO Guidelines for a number of vaccines, blood products and related substances. Specific discussion areas included WHO guidance on the production and evaluation of the quality, safety and efficacy of monoclonal antibodies as similar biotherapeutic products (SBPs); blood and blood components as essential medicines; estimation of residual risk of HIV, HBV or HCV infections via cellular blood components and plasma; snake antivenom immunoglobulins; human pandemic influenza vaccines in non-vaccine-producing countries; and clinical evaluation of vaccines: regulatory expectations. In addition, the following WHO guidance documents were also adopted: WHO manual for the preparation of secondary reference materials for in vitro diagnostic assays designed for infectious disease nucleic acid or antigen detection: calibration to WHO International Standards; and Human challenge trials for vaccine development: regulatory considerations. One WHO addendum document – Labelling information of inactivated influenza vaccines for use in pregnant women – was also adopted.
Subsequent sections of the report provide information on the current status, proposed development and establishment of international reference materials in the areas of: biotherapeutics other than blood products; blood products and related substances; cellular and gene therapies; in vitro diagnostics; and vaccines and related substances.